Bristol-Myers Squibb Co vs Progressive Corp — how do they compare? Bristol-Myers Squibb Co trades at $63.44 (market cap $129.94B), while Progressive Corp trades at $212.36 (market cap $123.45B). The key difference: Bristol-Myers Squibb Co and Progressive Corp are close in size by market cap, and Progressive Corp pays the higher dividend (6.55%). Which is the better fit depends on your goals.
| BMY | PGR | |
|---|---|---|
Market Cap | $129.94B | $123.45B |
Sector | Health | Financials |
52-Week High | $65.89 | $252.68 |
52-Week Low | $42.60 | $190.40 |
Enterprise Value | $163.92B | $131.66B |
Dividend Yield | 3.96% | 6.55% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Progressive (PGR) trades at $213.95, down 0.64% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamental performance with revenue growing from $49.6B in 2022 to $87.6B in 2025 and net income reaching $11.3B. Recent Q2 2026 earnings beat expectations at $4.85 per share, though the combined ratio widened to 87.1%, indicating potential growth trade-offs. Analyst consensus price target stands at $231.20 with 37% buy ratings.
PGR presents a compelling investment case with reasonable valuation (P/E 10.65) and strong profitability (ROE 34.94%), though investors face risks from competitive pressures and potential margin compression as the company expands its bundled insurance offerings. The stock offers 8% upside to consensus target with balanced risk-reward profile.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Progressive underwrites private and commercial auto insurance and specialty lines
Read more on PGR →